Akebia Therapeutics (AKBA) 10-Q2023 Q1 Quarterly report

Filed: 8 May 23, 7:50am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: AKI, aneumia, armed, Averoa, Biden, broader, caregiver, catastrophic, chill, CJEU, Colorado, compelling, Connecticut, CSL, dioxycarbonate, disposition, DMCC, eager, eighteen, enable, enabled, engendered, exceeding, excise, filer, forward, Hypophosphatemia, hypoxic, Iceland, IRA, ischemic, Jesduvroq, judgement, justification, laid, landscape, Latin, legitimize, length, Liechtenstein, lifecycle, LOE, maximizing, mifepristone, mission, Nicole, Norway, outsourced, parental, pivotal, PMR, presence, protracted, Renazorb, resubmitted, retinopathy, role, ROP, sanction, Secretary, steering, substituted, symptomatic, terrorist, tied, Turkey, Unicycive, unmet, USA, user, Utah, Virginia, worsening

Removed: AB, Abraham, adequacy, aggressively, Albert, alleviate, amending, Andreula, applicant, appointed, autonomy, blood, carried, cell, characterization, characterize, Chen, classify, combined, compensatory, consolidate, constraint, context, contingency, contra, correct, correctly, Corwin, costing, counted, counter, counterpart, counterparty, deadline, declaration, declaratory, dedicate, degree, denied, Deputy, Designated, detected, discontinued, discovered, dismissal, disruption, distinguished, document, documented, dosing, doubt, Eastern, EDNY, elucidated, emerge, executory, exercising, expedited, explanatory, Facilitation, finalizing, flexible, focal, Glaxo, hedging, holder, home, honored, Hsing, Hulst, importance, improved, independence, Inferior, inhibiting, inspection, IP, IQVIA, Janssen, JP, kilogram, Kiswani, Lasker, Likewise, liquidate, misstatement, mitigating, mix, modification, Nobel, NV, optional, outlook, pattern, pertaining, Pharmaceutica, placebo, plaintiff, posed, prevented, Prize, PRV, pyridine, RBC, realization, realized, recoverability, red, reflecting, remediated, remediation, resale, rescissory, resume, resuming, retroactive, revoke, Rosenblatt, ruled, segmental, separately, situation, Social, stabilization, step, sublicensable, Substantive, summarize, survival, technique, tested, unavailability, understand, undertook, unemployment, valuation, Van, vendor, verification, voluntarily, Voucher, warrant, week, withhold, workplace, worried

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AKBA transcripts

AKBA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. Section 1350)

In connection with the accompanying Quarterly Report of Akebia Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023 (the “Report”), I, John P. Butler, as Chief Executive Officer and President of the Company, and I, David A. Spellman, as Senior Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 8, 2023	By:	/s/ John P. Butler
		John P. Butler
		President, Chief Executive Officer and Director
		(Principal Executive Officer)

Date: May 8, 2023	By:	/s/ David A. Spellman
		David A. Spellman
		Senior Vice President, Chief Financial Officer and Treasurer
		(Principal Financial Officer and Principal Accounting Officer)